JAMA Network·· 20 hours agoPickScore75
Lipoprotein(a)-Lowering Agent Fails to Reduce Cardiovascular Events
In brief
Pelacarsen did not reduce adverse cardiovascular events in a phase 3 trial despite lowering Lp(a) levels, according to an announcement from the manufacturer.
Why it matters
Phase 3 showed no cardiovascular event reduction despite marked Lp(a) lowering, a key negative test of the Lp(a) hypothesis.
Source: JAMA Network · jamanetwork.com